lymphoma
CAR T-Cell Therapies Targeting CD20 Show Early Potential to Prevent, Mitigate NHL Relapse
Studies of two CAR T-cell products showed encouraging response rates but raised questions about where CD20 targeting fits into lymphoma treatment sequencing.
Novartis On Track to Pursue Kymriah Approval in Follicular Lymphoma After Promising Results
The firm announced positive data from the Phase II ELARA trial and said it will seek regulatory approval for the CAR T-cell therapy in refractory follicular lymphoma.
Mustang Bio to Study CAR T-Cell Therapy in CD20-Positive Lymphoma, Leukemia Patients
The FDA accepted Mustang's IND for MB-106, allowing the firm to begin a Phase I/II trial later this year in patients with certain CD20-positive blood cancers. Â
Humanigen's Lenzilumab With CAR T-Cell Therapy Improves Response in Lymphoma
The firm will initiate a Phase II registrational study of lenzilumab with all commercially available CD19 CAR T-cell therapies in diffuse large B-cell lymphoma.
Vincerx Pharma to Begin Phase Ib Trial in MYC-Driven Lymphoma
The study expands on another trial evaluating VIP152 in solid tumors and blood cancers that have an MYC overexpression or translocation.